Special Issue

Modern Pathology, Artificial Intelligence and Personalized Therapy in Gastrointestinal Cancer

Message from the Guest Editor

Advancements in technology and molecular diagnostics have increased our understanding and interpretation of the genomic and proteomic properties of cancers, and revealed many specific biomarkers that are now being incorporated into diagnostic and treatment decision-making algorithms. Molecular pathology is rapidly becoming a cornerstone of personalized therapy for cancers, including GI cancers. This Special Issue of *Cancers* aims to introduce the latest original studies and reviews on molecular biomarkers, digital pathology, and personalized therapy in GI cancers.

Guest Editor

Dr. Wenqing Cao

NYU Grossman School of Medicine, New York, NY, USA

Deadline for manuscript submissions

31 August 2025

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)